Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 797 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Celgene Clear all
Terminated Phase 3 Interventional Results available

A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease

NCT02641392
View directory record Official record
Conditions
Crohn's Disease
Interventions
GED-0301, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
12 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
San Diego, California • Atlanta, Georgia • Indianapolis, Indiana + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 15, 2026, 4:53 PM EDT
Terminated Phase 1 Interventional

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT04975399
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CC-92328
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 15, 2026, 4:53 PM EDT
Completed Phase 2 Interventional Results available

Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)

NCT02573493
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of the Head and Neck, Cancer of Head and Neck, Cancer of the Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck
Interventions
nab-Paclitaxel, Cisplatin, Cetuximab, Intensity-Modulated Radiation Therapy
Drug · Biological · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
3
States / cities
Westwood, Kansas • St Louis, Missouri • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 15, 2026, 4:53 PM EDT
Completed Phase 2 Interventional Results available

Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

NCT00179673
View directory record Official record
Conditions
Non-Hodgkins Lymphoma
Interventions
Lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
11
States / cities
Scottsdale, Arizona • Berkeley, California • Fountain Valley, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 15, 2026, 4:53 PM EDT
Completed Phase 2 Interventional Results available

Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.

NCT01928576
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Epigenetic Therapy
Interventions
Azacitidine, Entinostat, Nivolumab, CC-486 300
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 15, 2026, 4:53 PM EDT
Completed Phase 1 Interventional

Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib

NCT00667147
View directory record Official record
Conditions
Solid Tumors
Interventions
Weekly Abraxane and Daily Vandetanib, Abraxane every three weeks and daily vandetanib
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 15, 2026, 4:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects

NCT03824678
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
CC-220
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 15, 2026, 4:53 PM EDT
Terminated Phase 2 Interventional Results available

Prevention of Restenosis Following Revascularization

NCT00518284
View directory record Official record
Conditions
Vascular Disease, Peripheral
Interventions
Nanoparticle Paclitaxel
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Sacramento, California • Gainsville, Florida • Davenport, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Oct 15, 2026, 4:53 PM EDT
Terminated Phase 2 Interventional Results available

Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma

NCT00843310
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide (Revlimid), Melphalan, Dexamethasone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 15, 2026, 4:53 PM EDT
Completed Phase 2 Interventional Results available

Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia

NCT00759603
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Lenalidomide, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2015 · Synced Oct 15, 2026, 4:53 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis

NCT02576717
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
RPC1063
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
2,494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
19
States / cities
Phoenix, Arizona • Berkeley, California • Fresno, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 15, 2026, 4:53 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study

NCT01054196
View directory record Official record
Conditions
Multiple Myeloma
Interventions
lenalidomide, melphalan
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 15, 2026, 4:53 PM EDT
Completed Phase 2 Interventional Results available

Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma

NCT01159574
View directory record Official record
Conditions
Multiple Myeloma
Interventions
dexamethasone, clarithromycin, Pomalidomide
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 15, 2026, 4:53 PM EDT
Completed Phase 1 Interventional Results available

Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)

NCT01373229
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
Lenalidomide + Plerixafor (+ Rituximab)
Drug
Lead sponsor
David Rizzieri, MD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 15, 2026, 4:53 PM EDT
Terminated Phase 1 Interventional Results available

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

NCT02848001
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions
CC-90009
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
6
States / cities
Stanford, California • New Haven, Connecticut • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 15, 2026, 4:53 PM EDT
Completed No phase listed Observational

Multi-center Database Registry to Study Thalamus Changes Using AI in MS

NCT03920995
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 85 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 15, 2026, 4:53 PM EDT
Terminated Phase 2 Interventional Results available

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer

NCT00281528
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
ABI-007 (Abraxane), bevacizumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Female only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
39
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Fresno, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 15, 2026, 4:53 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

NCT02616965
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma (CTCL)
Interventions
Romidepsin, Brentuximab vedotin
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 15, 2026, 4:53 PM EDT
Completed Phase 2 Interventional Results available

Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)

NCT00813124
View directory record Official record
Conditions
Stem Cell Transplantation, Leukemia
Interventions
Fludarabine, Busulfan, Thymoglobulin, Azacitidine, Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 15, 2026, 4:53 PM EDT
Completed Phase 1 Interventional

Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)

NCT00864942
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma
Interventions
bendamustine and lenalidomide, BL-NHL, BLR-CLL, BLR-NHL
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2015 · Synced Oct 15, 2026, 4:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

NCT02431559
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Durvalumab, Pegylated Liposomal Doxorubicin, Motolimod
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
4
States / cities
Phoenix, Arizona • New York, New York • Hilliard, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 15, 2026, 4:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC

NCT01757288
View directory record Official record
Conditions
STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER
Interventions
NAB-PACLITAXEL, PACLITAXEL
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
5
States / cities
Rochester, New York • Pittsburgh, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 15, 2026, 4:53 PM EDT
Completed Phase 2 Interventional Results available

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

NCT01036087
View directory record Official record
Conditions
Breast Cancer
Interventions
Panitumumab, Nab-paclitaxel, Carboplatin, 5-Fluorouracil, Epirubicin, Cyclophosphamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 15, 2026, 4:53 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Apremilast Pregnancy Exposure Registry

NCT02775500
View directory record Official record
Conditions
Psoriatic Arthritis, Psoriasis
Interventions
apremilast
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Female only
Enrollment
233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 15, 2026, 4:53 PM EDT